Asset Details
Do you wish to reserve the book?
Trabectedin is a promising antitumor agent potentially inducing melanocytic differentiation for clear cell sarcoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Trabectedin is a promising antitumor agent potentially inducing melanocytic differentiation for clear cell sarcoma
Do you wish to request the book?
Trabectedin is a promising antitumor agent potentially inducing melanocytic differentiation for clear cell sarcoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Trabectedin is a promising antitumor agent potentially inducing melanocytic differentiation for clear cell sarcoma
2017
Overview
Clear cell sarcoma is an aggressive soft tissue sarcoma and highly resistant to conventional chemotherapy and radiation therapy. This devastating disease is defined by EWSR1‐ATF1 fusion gene resulting from chromosomal translocation t(12;22)(q13;q12) and characterized by melanocytic differentiation. A marine‐derived antineoplastic agent, trabectedin, inhibits the growth of myxoid liposarcoma and Ewing sarcoma by causing adipogenic differentiation and neural differentiation, respectively. In this study, we examined the antitumor effects and mechanism of action of trabectedin on human clear cell sarcoma cell lines. We showed that trabectedin decreased the cell proliferation of five clear cell sarcoma cell lines in a dose‐dependent manner in vitro and reduced tumor growth of two mouse xenograft models. Flow cytometry and immunoblot analyses in vitro and immunohistochemical analysis in vivo revealed that trabectedin‐induced G2/M cell cycle arrest and apoptosis. Furthermore, trabectedin increased the expression of melanocytic differentiation markers along with downregulation of ERK activity in vitro and the rate of melanin‐positive cells in vivo. These results suggest that trabectedin has potent antitumor activity against clear cell sarcoma cells by inducing cell cycle arrest, apoptosis, and, in part, by promoting melanocytic differentiation through inactivation of ERK signaling. Our present study indicates that trabectedin is a promising differentiation‐inducing agent for clear cell sarcoma. Clear cell sarcoma is an aggressive soft‐tissue sarcoma and highly resistant to conventional chemotherapy and radiation therapy. Our present study suggests that trabectedin has potent antitumor activity against clear cell sarcoma cells by inducing cell cycle arrest, apoptosis, and, in part, by promoting melanocytic differentiation.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc
Subject
/ Animals
/ Antineoplastic Agents, Alkylating - administration & dosage
/ Antineoplastic Agents, Alkylating - pharmacology
/ Cell Proliferation - drug effects
/ Cell Survival - drug effects
/ Dioxoles - administration & dosage
/ Dose-Response Relationship, Drug
/ Humans
/ Kinases
/ Melanin
/ Mice
/ Rodents
/ Sarcoma, Clear Cell - drug therapy
/ Tetrahydroisoquinolines - administration & dosage
/ Tetrahydroisoquinolines - pharmacology
